Quercetin-3-rutinoside hydrate is a plant pigment (flavonoid) widely distributed in many fruits and
vegetables known as rutin. Its therapeutic properties are mainly attributed to its potent antioxidant and
anti-inflammatory activities. Its effect is well known as an antimicrobial, antifungal, and anti-allergic
agent while extensive research has shown its multi-spectrum pharmacological benefits in cancer,
diabetes, hypertension, hypercholesterolemic conditions, and neurodegenerative conditions.
Currently, no clear-cut remedies available to prevent the progression of Cognitive impairment (CI)
along with that one major pharmaceutical constraint associated with rutin is bioavailability, aqueous
solubility, and stability. CI are a state which includes loss in comprehension with perception, logic,
planning, attention, judgment, and memory. It is associated with Alzheimer's, Parkinson’s, dementia,
head injury, schizophrenia, cerebrovascular impairment, and depressive disorder. The present review
emphasizes the current knowledge available for rutin in the treatment of CI, its mechanism of action,
and molecular targets based on preclinical research. Clinical trials, toxicity profiles, and formulation
development are also mentioned in this report. Rutin is a treasure of the garden have diversified health
benefits due to its restoration of PARP activity, P-95, reversal of the levels of BACE 1 and p-STAT3,
ameliorated synaptophysin protein expression in the hippocampus, and partly reversed the level of
dopamine and decreased expression of Bcl-xL and Bcl-2. Novel formulation of rutin is overcoming
the pharmaceutical challenges and bring this to the forefront as an alternative therapy in CI and other
diseases.
Keywords: Neurodegeneration; Rutin; Cognitive impairment; Novel formulation;
Pharmaceutical challenge
Publication date: 01/02/2022
https://ijbpas.com/pdf/2022/February/MS_IJBPAS_2022_5872.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.2.5872
